Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
InAlyzer - The technology chosen by NASA
Jul 10, 2023
MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research
Nature Article: The genomic landscape of pediatric acute lymphoblastic leukemia
Jun 29, 2023
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and...
Brain-specific biomarkers in urine as a non-invasive approach to monitor neuronal and glial damage
Jun 28, 2023
This study evaluates the quantitative measurability of glial fibrillary acidic protein (GFAP), neurofilament light...
PET from Molecubes for imaging of neuroendocrine tumors
Jun 28, 2023
Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors:...
Aug 5, 2016
Preclinical in vivo molecular imaging is widely regarded as a key tool within the drug discovery and development pipeline, giving researchers clear visibility of cellular changes at a molecular level. Techniques – or modalities – such as optical, PET and SPECT imaging provide high specificity and wide applicability, as well as the ability to monitor several molecular events and identify key molecular markers. The result is a deeper understanding of disease progression, and the mode of action and pharmacokinetics of potential therapeutics.
If we consider small animal optical imaging systems specifically, these now enable researchers to combine a number of imaging modalities using the same instrument, thereby paving the way for a better understanding of physiological and disease mechanisms in the preclinical setting. For example, one such system provides five imaging modalities as standard, allowing for co-registration of molecular events with access to bioluminescence, multispectral VIS-NIR fluorescence, unique direct radioisotopic imaging, and Cerenkov radiation. A high speed digital X-ray scanner adds to the functional images with morphological features.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging | PET, SPECT, CT
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/